Dr Gail Holland

Research Highlights

1. Gregory, J., Carter, K., Cheung, I., Holland, G., Bowen-Morris, J., Luzio, S., Dunseath, G., Tree, T., Yang, J., Marwaha, A., Ali, M., Bashir, N., Hutchings, H., Fegan, G., Stenson, R., Hiles, S., Marques-Jones, S., Brown, A., Tatovic, D., & Dayan, C. (2021). Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open, 11(10), e049595

   https://doi.org/10.1136/bmjopen-2021-049595, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa58417
2. Hutchings, H., Lanyon, K., Lister, S., Alikhan, R., Halcox, J., Holland, G., Hughes, A., Jenkins, R., Laing, H., Lobban, T., Owen, D., Pollock, K., Todd, C., & Wareham, K. (2022). Investigating the feasibility of recruitment to an observational, quality-of-life study of patients diagnosed with atrial fibrillation (AF) who have experienced a bleed while anticoagulated: EQUAL-AF feasibility study protocol. Pilot and Feasibility Studies, 8(1)

   https://doi.org/10.1186/s40814-022-01135-8, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa60803
3. Tatovic, D., McAteer, M., Barry, J., Barrientos, A., Terradillos, K., Perera, I., Kochba, E., Levin, Y., Dul, M., Coulman, S., Birchall, J., Ruhland, C., Howell, A., Stenson, R., Ali, M., Luzio, S., Dunseath, G., Cheung, W., Holland, G...., & Cheung, I. (2022). Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes. Immunotherapy Advances, 2(1)

   https://doi.org/10.1093/immadv/ltac002, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa61405
4. Hutchings, H., Lanyon, K., Holland, G., Alikhan, R., Jenkins, R., Laing, H., Hughes, A., Lobban, T., Pollock, K., Tod, D., & Lister, S. (2023). Can we collect health-related quality of life information from anticoagulated atrial fibrillation participants who have recently experienced a bleed? An observational feasibility study in primary and secondary care in Wales and through a UK online forum. BMJ Open, 13(10), e075335

   https://doi.org/10.1136/bmjopen-2023-075335, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa64676

   http://dx.doi.org/10.1136/bmjopen-2023-075335
5. Tatovic, D., Marwaha, A., Taylor, P., Hanna, S., Carter, K., Cheung, I., Luzio, S., Dunseath, G., Hutchings, H., Holland, G., Hiles, S., Fegan, G., Williams, E., Yang, J., Domingo-Vila, C., Pollock, E., Wadud, M., Ward-Hartstonge, K., Marques-Jones, S...., & Group), . (2024). Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine, 30, 2657-2666.

   https://doi.org/10.1038/s41591-024-03115-2, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa67256

All Research